Legal news

DELSOL Avocats is proud to be ranked in 10 Legal 500 EMEA 2024 categories : Construction – Tier 3 Data privacy and data protection – Tier 3 Dispute resolution : Commercial litigation – Tier 4 Dispute resolution : White-collar crime – Tier 4 Employment –

DELSOL Avocats has once again been distinguished at the Palmarès du Droit organised in Paris by Le Monde du Droit. The expertise of our teams was rewarded in the following categories : Tax Litigation : Golden trophy Wealth law : Golden trophy Non-profit organisations : Golden trophy Mergers - Acquisitions : transactions < €50M : Silver...

DELSOL Avocats is proud to be listed in 3 Chambers and Partners 2024 rankings : Corporate/M&A : Mid-Market - Band 3 Litigation : Highly Regarded - Band 3 General Business Law - Spotlight In addition to these collective rankings,Gaëlle MERLIER has been designated « Up and Coming » lawyer in « Pharma/Life Sciences : Product Liability » and...

Charles Price participated as an arbitrator in the 2024 Brussels Pre Moot organized by White & Case and Linklaters in preparation for the 31st Willem C. Vis International Commercial Arbitration Moot to be held in Hong Kong on 10 -17 March and in Vienna on 22 - 28 March. 👉 Information and...

Article 116 of the Finance Law for 2024, published in the Journal Officiel on December 30, 2023, confirmed measures with a substantial impact on transfer pricing. These evolutions are reflected in a reinforcement of the documentary obligations imposed on companies, but also in measures designed to reinforce audits by the tax authorities. In...

DELSOL Avocats is delighted to announce the promotion to Counsel status of three lawyers : Caroline Da Lage (Mergers & Acquisitions - Corporate Law), Jessica Neufville (Employment Law – Social welfare law, Distressed companies - Restructuring) and Arnaud Laroche (Non-profit Organisations - Social and solidarity-based entrepreneurship)....

What is a biosimilar product ? A biosimilar is a biological medicine (i.e., a medicine whose active substance is made by a living organism) highly similar to another already approved biological medicine (the « reference medicine »EMA, [1]) . According to the European Medicines Agency (« EMA »), biosimilar medicines have become major therapeutic...

Digital platforms are major players in our economy and this fact caught the attention of the European institutions. At the heart of their business model is the involvement of platform workers, to whom these companies subcontract all or part of a service. According to Brussels, there are 28 million platform workers in the Member States, 5.5...

Before 2024, there was no uniform federal procedure in the United States for reporting beneficial ownership. As we step into 2024, the Corporate Transparency Act (CTA) comes into effect, requiring a wide range of businesses to disclose their beneficial ownership details to the Financial Crimes Enforcement Network (FinCEN), a division of the...